Chenyu Pi

CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy

Lijun Xu, K. Xie, Jianmin Fang, 2018, Oncoimmunology.

Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression.

Jingming Zhang, T-G Huang, K. Xie, 2021, International immunopharmacology.

Reversing PD-1 Resistance in B16F10 Cells and Recovering Tumour Immunity Using a COX2 Inhibitor

T-G Huang, K. Xie, Yan Feng, 2022, Cancers.

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity

Yan Feng, Jingming Zhang, K. Xie, 2022, Life.

A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+ tumors in hPD-1 transgenic mouse model and contributes immune memory formation

Jingming Zhang, Ruiqin Wang, K. Xie, 2021, Breast Cancer Research and Treatment.

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade

K. Xie, Yan Feng, Jian-min Fang, 2022, Journal for ImmunoTherapy of Cancer.

Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo

J. Larrick, Lijun Xu, A. Mendelsohn, 2017, Oncotarget.

Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitope

Hua Gu, Chenyu Pi, Genhui Zheng, 2023, Signal transduction and targeted therapy.